Tempest and Millendo Announce Stockholder Approval of Merger

June 22, 2021

– Tempest to Trade on Nasdaq Public Markets Under Ticker “TPST”

South San Francisco, CA, and Ann Arbor, Mich.  June 22, 2021 –Tempest Therapeutics, Inc. (“Tempest”), a clinical-stage oncology company developing potentially first-in-class therapeutics that combine both targeted and immune-mediated mechanisms, and Millendo Therapeutics, Inc. (Nasdaq: MLND) (“Millendo”), announced today the results for the proposals voted upon by Millendo stockholders at a Special Meeting on June 22, 2021. The stockholders voted in favor of all proposals at the Special Meeting, including to approve the proposed merger between the companies.

The closing of the merger is anticipated to take place on or around Friday, June 25, 2021. Following the closing of the merger, the combined company will be renamed Tempest Therapeutics and shares will begin trading with the open of the market on Monday, June 28, 2021 under the ticker “TPST.”

Read more

Posted in Uncategorized